Whitehawk Therapeutics, Inc.
US ˙ NasdaqCM ˙ US00032Q1040

SecurityWHWK / Whitehawk Therapeutics, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Squarepoint Ops LLC closes position in WHWK / Whitehawk Therapeutics, Inc.

On February 13, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 0 shares of Whitehawk Therapeutics, Inc. (US:WHWK) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 83,660 shares of Whitehawk Therapeutics, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F WHITEHAWK THERAPEUTICS COM 00032Q104 0 -100.00 0
2025-11-14 2025-09-30 13F WHITEHAWK THERAPEUTICS COM 00032Q104 83,660 22,294 36.33 159 38.60 0.0002
2025-08-27 2025-06-30 13F/A-1 WHITEHAWK THERAPEUTICS COM 00032Q104 61,366 61,366 115 0.0001
2025-08-14 2025-06-30 13F WHITEHAWK THERAPEUTICS COM 00032Q104 61,366 61,366 115 0.0001
2025-02-14 2024-12-31 13F AADI BIOSCIENCE COM 00032Q104 0 -10,510 -100.00 0 -100.00
2024-11-14 2024-09-30 13F AADI BIOSCIENCE COM 00032Q104 10,510 -10,120 -49.05 22 -30.00 0.0000
2024-08-14 2024-06-30 13F AADI BIOSCIENCE COM 00032Q104 20,630 20,630 30 0.0000
2024-05-15 2024-03-31 13F AADI BIOSCIENCE COM 00032Q104 0 -46,164 -100.00 0 -100.00
2024-02-14 2023-12-31 13F AADI BIOSCIENCE COM 00032Q104 46,164 22,565 95.62 93 -18.42 0.0002
2023-11-14 2023-09-30 13F AADI BIOSCIENCE COM 00032Q104 23,599 3,656 18.33 114 -16.18 0.0003
2023-08-14 2023-06-30 13F AADI BIOSCIENCE COM 00032Q104 19,943 -838 -4.03 136 -9.33 0.0004
2023-05-15 2023-03-31 13F AADI BIOSCIENCE COM 00032Q104 20,781 20,781 150 0.0006
2023-02-14 2022-12-31 13F AADI BIOSCIENCE COM 00032Q104 0 -16,317 -100.00 0 -100.00
2022-11-14 2022-09-30 13F AADI BIOSCIENCE COM 00032Q104 16,317 16,317 231 0.0012
2022-08-15 2022-06-30 13F AADI BIOSCIENCE COM 00032Q104 0 -20,416 -100.00 0 -100.00
2022-05-16 2022-03-31 13F AADI BIOSCIENCE COM 00032Q104 20,416 20,416 346 0.0015
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.